Sinotherapeutics (SH:688247) Ge Long Hui A P P·2025-12-08 08:37Core Viewpoint - XuanTai Pharmaceutical (688247.SH) has successfully renewed the inclusion of its product, Sitagliptin Metformin Extended-Release Tablets (II), in the National Medical Insurance Catalog (2025) through a national negotiation process, indicating recognition of the drug's clinical value by the National Healthcare Security Administration [1] Summary by Relevant Categories Product Inclusion - The Sitagliptin Metformin Extended-Release Tablets (II) have been renewed for inclusion in the National Medical Insurance Catalog, reflecting the government's acknowledgment of its clinical value [1] Market Impact - The inclusion in the insurance catalog is expected to enhance the affordability and accessibility of the drug for patients, which will facilitate market promotion and increase sales scale [1] Long-term Development - This development is viewed positively for the company's long-term operational growth, as it aligns with the goal of benefiting more patients through improved healthcare policies [1]